Table 1 Summary of key resource use observed in the OASIS-5 trial patients randomized in Canada (n = 1.403) within the 180-day follow-up period together with associated unitcosts (adapted from Table 2 in US analysis’)
Fondaparinux | Enoxaparin | ||
|---|---|---|---|
Item of resource use | (n = 701) | (n = 7 02) | Unit cost (CAD 2009 S) |
Sudy drugs (mean (SD) days) | 4.10 (2.28) | 3.65 (2.11) | Enoxaparin: 15 per day a |
Fondaparinux: 15 per day b | |||
Days in hospital (mean (SD)) | |||
ICU | 3.54 (5.07) | 3.57 (3.83) | 1433 per day |
General ward | 4.64 (10.13) | 4.46 (9.61) | 547 per day |
Step down | 2.98 (5.01) | 2.85 (5.28) | 547 per day |
Selected concomitant medicines | |||
Clopidcgrel (mean (SD) days) | 105.25 (77.18) | 106.07 (77.69) | 2.58 per day |
Ticlopidine (mean (SD) days) | 0.08 (1.75) | 1.04 (12.14) | 0.55 per day |
Glycoprotein llb/llla antagonists (n (%)) | 201 (28.67) | 212 (30.20) | 1094 |
Selected procedures (n (%) with one or more) | 47 (6.70) | 39 (5.56) | 543 per procedure |
Blood transfusion | 603 (86.02) | 607 (86.47) | 5401 per procedure |
Coronary angiography | 298 (42.51) | 335 (47.72) | 10,543 per procedure |
Percutaneous coronary intervention | 143 (20.40) | 134 (19.09) | 21,286 per procedure |
Coronary artery bypass graft |